Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 22.22% on an annualized basis producing an average annual return of 33.3...
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is...
BioNTech SE (NASDAQ: BNTX) has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its holdings, with a significant sale of DraftKings Inc (NASDAQ:DKNG) shares an...
Risk appetite is surging again Thursday on Wall Street, with investors welcoming the Federal Reserve’s decision to keep rates unchanged and F...
Moderna Inc (NASDAQ: MRNA) shares are trading lower after the company reported a deeper Q3 loss of $(9.53), down from EPS income of $2.53. The...
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick...
The Nasdaq 100 closed higher by 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could b...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...